Catalyst Oncology is a specialty oncology clinical research organization (CRO) devoting time, energy, and capital to supporting biotechs in bringing next-generation immuno-oncology (IO) therapies to cancer patients in need. Oncology clinical research is complex, demanding, and continually evolving. Bringing effective IO therapies to proof-of-concept and then to market as fast as possible is our mission because every second counts for patients and their families living with cancer.
>40% of our active oncology portfolio is IO
- Cell therapies (CAR-T, TILs)
- Autologous and allogeneic
- Hematologic malignancies and solid tumors
- Biospecifics
- T-cell and macrophage engagers
- Tumor microenvironment remodellers
- Oncolytic viruses
- Vaccines
- Gene therapies
- Novel checkpoints
We understand the nuances of IO trials
- Complex modalities (live cells, viruses, bispecific antibodies)
- Safety/toxicity profiles (CRS, ICANS, TLS, delayed reactions)
- Novel endpoints and study designs (iRECIST, mTPI, BOIN)
- Biomarker involvement; increased data collection
- Coordination of numerous vendors
Active Next-generation oncology experience
Working both locally and globally across Phases I through III in a range of solid tumor and hematologic indications, we understand the nuances of complex study designs, novel endpoints, and cutting-edge technologies.
